In a first study of its kind, researchers have found that the FDA-approved “safe” daily exposure amount of BPA may be altering insulin release which may be enough to have implications for the development of Type 2 diabetes and other metabolic diseases.

In a first study of its kind, researchers have found that the FDA-approved “safe” daily exposure amount of BPA may be altering insulin release which may be enough to have implications for the development of Type 2 diabetes and other metabolic diseases.: https://ift.tt/2QyOvz7 Read more... https://ift.tt/2OwWxHv